title: Clinical relevance of circulating immune complexes in human leukemia. Association in acute leukemia of the presence of immune complexes with unfavorable prognosis.
abstract: The occurrence of circulating immune complexes was investigated in 467 serum samples from 230 leukemia patients using the [(125)I]Clq-binding test. There was an increased serum [(125)I]Clq-binding activity in 40% of patients with acute myeloid leukemia, 23% with acute lymphatic leukemia, 46% in blastic crisis of chronic myeloid leukemia, 12% with chronic lymphatic leukemia, and 13% with chronic myeloid leukemia. In 48 patients, serum was also tested for soluble immune complexes by the Raji cell radioassay; the correlation between results of the two tests was significant. The Clq-binding material had properties identical with those of immune complexes. It sedimented as 14-28s material on sucrose density gradient. It contained IgG which could be dissociated at acid pH. Its Clq-binding properties could be removed after passage through anti-IgG immuno-absorbant or after a mild reduction-alkylation treatment, but were not sensitive to deoxyribonuclease treatment. Circulating immune complexes were found most commonly during the blastic stage of leukemia.Remission took place in 75.4% of patients with no detectable circulating immune complexes at the onset of acute leukemia, but in only 32.7% of those with detected complexes during this period. Median survival times of the former group of patients were more than 18 mo in acute myeloid leukemia and acute lymphatic leukemia and more than 8(1/2) mo in blastic crisis of chronic myeloid leukemia. The corresponding median survival times in the latter patient group were 64, 135, and 90 days. These findings were unrelated to prognostic features already known.
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000936:Antigen-Antibody Complex; D002460:Cell Line; D002648:Child; D003172:Complement C1 / Q000378:metabolism; D005260:Female; D006680:HLA Antigens; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007518:Isoantibodies / Q000032:analysis; D007938:Leukemia / Q000276:immunology* / Q000473:pathology; D007945:Leukemia, Lymphoid / Q000276:immunology; D007951:Leukemia, Myeloid / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000276:immunology; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D011379:Prognosis
chemical_list: D000936:Antigen-Antibody Complex; D003172:Complement C1; D006680:HLA Antigens; D007074:Immunoglobulin G; D007518:Isoantibodies
references.citation: Int Arch Allergy Appl Immunol. 1955;7(2):103-10
references.pmid: 13262900
references.citation: J Biol Chem. 1961 May;236:1372-9
references.pmid: 13767412
references.citation: Clin Exp Immunol. 1976 Nov;26(2):189-95
references.pmid: 136325
references.citation: Lancet. 1974 Jun 29;1(7870):1318-20
references.pmid: 4134298
references.citation: Proc Natl Acad Sci U S A. 1971 Jun;68(6):1372-5
references.pmid: 5288389
references.citation: J Exp Med. 1974 Oct 1;140(4):877-94
references.pmid: 4139225
references.citation: Cancer. 1974 Oct;34(4 Suppl):suppl:1446-51
references.pmid: 4370857
references.citation: Cancer Res. 1974 May;34(5):1179-81
references.pmid: 4276372
references.citation: Cancer. 1974 Oct;34(4 Suppl):suppl:1469-73
references.pmid: 4609389
references.citation: Intervirology. 1974;4(5):292-302
references.pmid: 4377147
references.citation: Proc Natl Acad Sci U S A. 1974 Mar;71(3):685-9
references.pmid: 4595570
references.citation: J Natl Cancer Inst. 1974 May;52(5):1435-44
references.pmid: 4208711
references.citation: Isr J Med Sci. 1971 Jan;7(1):111-31
references.pmid: 5549279
references.citation: J Natl Cancer Inst. 1973 Mar;50(3):633-44
references.pmid: 4267705
references.citation: Nat New Biol. 1972 Aug 9;238(84):185-6
references.pmid: 4340574
references.citation: Clin Exp Immunol. 1974 Oct;18(2):237-42
references.pmid: 4283118
references.citation: Nature. 1973 Jan 12;241(5385):95-100
references.pmid: 4121144
references.citation: J Clin Invest. 1974 Dec;54(6):1273-8
references.pmid: 4140196
references.citation: Int J Cancer. 1974 Jun 15;13(6):824-38
references.pmid: 4136591
references.citation: J Immunol Methods. 1972 Nov;2(1):25-34
references.pmid: 4139208
references.citation: Immunology. 1968 Mar;14(3):415-23
references.pmid: 4170512
references.citation: J Lab Clin Med. 1967 May;69(5):749-57
references.pmid: 4164824
references.citation: Clin Exp Immunol. 1969 Jan;4(1):65-82
references.pmid: 4182356
references.citation: Nature. 1974 Oct 18;251(5476):648-50
references.pmid: 4153575
references.citation: Science. 1974 Jan 11;183(4120):94-6
references.pmid: 4148704
references.citation: Nature. 1973 Nov 16;246(5429):146-8
references.pmid: 4148474
references.citation: Nature. 1968 Dec 28;220(5174):1352-4
references.pmid: 4302696
references.citation: Lancet. 1976 Feb 28;1(7957):449-51
references.pmid: 55719
references.citation: Lancet. 1976 Jun 5;1(7971):1249
references.pmid: 58301
references.citation: Int J Cancer. 1976 Sep 15;18(3):310-6
references.pmid: 783053
references.citation: J Immunol. 1974 Dec;113(6):1876-82
references.pmid: 4214865
references.citation: Transplant Rev. 1975;27:100-34
references.pmid: 52924
references.citation: N Engl J Med. 1973 Sep 6;289(10):520-2
references.pmid: 4579334
references.citation: Clin Exp Immunol. 1973 Jun;14(2):159-67
references.pmid: 4577850
references.citation: N Engl J Med. 1973 Jan 25;288(4):169-75
references.pmid: 4565852
references.citation: Immunology. 1975 Mar;28(3):535-42
references.pmid: 47837
references.citation: J Natl Cancer Inst. 1974 May;52(5):1529 36
references.pmid: 4598556
references.citation: N Y State J Med. 1973 May 15;73(10):1180-5
references.pmid: 4512241
references.citation: Int J Cancer. 1972 Mar 15;9(2):274-83
references.pmid: 4504846
references.citation: Science. 1974 Nov 1;186(4162):454-6
references.pmid: 4413334
references.citation: Cancer. 1974 Oct;34(4 Suppl):suppl:1452-60
references.pmid: 4422494
references.citation: J Clin Invest. 1976 Jan;57(1):169-82
references.pmid: 128562
references.citation: J Clin Invest. 1974 Jul;54(1):128-37
references.pmid: 4857905
references.citation: J Immunol. 1973 Mar;110(3):820-8
references.pmid: 4734666
references.citation: Cell Immunol. 1972 Mar;3(3):341-60
references.pmid: 5013308
references.citation: Immunochemistry. 1975 Apr;12(4):273-8
references.pmid: 811545
references.citation: J Clin Invest. 1975 Aug;56(2):331-8
references.pmid: 807598
references.citation: N Engl J Med. 1971 Nov;285(22):1211-6
references.pmid: 5286519
references.citation: Cancer Res. 1976 Jan;36(1):43-7
references.pmid: 764968
references.citation: J Natl Cancer Inst. 1975 Dec;55(6):1281-9
references.pmid: 1107571
references.citation: Clin Immunol Immunopathol. 1975 Sep;4(3):374-81
references.pmid: 1104228
references.citation: Clin Exp Immunol. 1976 Jan;23(1):83-90
references.pmid: 1063068
references.citation: Clin Exp Immunol. 1976 Jun;24(3):379-84
references.pmid: 780020
references.citation: Int J Cancer. 1975 Jun 15;15(6):995-9
references.pmid: 1056897
references.citation: J Immunol. 1976 Jan;116(1):232-5
references.pmid: 1245740
references.citation: Eur J Cancer. 1975 Jun;11(6):451-5
references.pmid: 1172467
references.citation: Clin Exp Immunol. 1971 Aug;9(2):193-9
references.pmid: 5570677
references.citation: Int J Cancer. 1971 Mar 15;7(2):226-37
references.pmid: 5104167
references.citation: Clin Exp Immunol. 1968 Nov;3(9):889-99
references.pmid: 5751874